252 related articles for article (PubMed ID: 15748888)
1. Cell responses to FGFR3 signalling: growth, differentiation and apoptosis.
L'Hôte CG; Knowles MA
Exp Cell Res; 2005 Apr; 304(2):417-31. PubMed ID: 15748888
[TBL] [Abstract][Full Text] [Related]
2. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
[TBL] [Abstract][Full Text] [Related]
3. PTHrP rescues ATDC5 cells from apoptosis induced by FGF receptor 3 mutation.
Yamanaka Y; Tanaka H; Koike M; Nishimura R; Seino Y
J Bone Miner Res; 2003 Aug; 18(8):1395-403. PubMed ID: 12929929
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor-1 rescues the mutated FGF receptor 3 (G380R) expressing ATDC5 cells from apoptosis through phosphatidylinositol 3-kinase and MAPK.
Koike M; Yamanaka Y; Inoue M; Tanaka H; Nishimura R; Seino Y
J Bone Miner Res; 2003 Nov; 18(11):2043-51. PubMed ID: 14606518
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth.
Gómez-Román JJ; Saenz P; Molina M; Cuevas González J; Escuredo K; Santa Cruz S; Junquera C; Simón L; Martínez A; Gutiérrez Baños JL; López-Brea M; Esparza C; Val-Bernal JF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):459-65. PubMed ID: 15701828
[TBL] [Abstract][Full Text] [Related]
6. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.
Ronchetti D; Greco A; Compasso S; Colombo G; Dell'Era P; Otsuki T; Lombardi L; Neri A
Oncogene; 2001 Jun; 20(27):3553-62. PubMed ID: 11429702
[TBL] [Abstract][Full Text] [Related]
7. Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1.
Harada D; Yamanaka Y; Ueda K; Nishimura R; Morishima T; Seino Y; Tanaka H
Bone; 2007 Aug; 41(2):273-81. PubMed ID: 17561467
[TBL] [Abstract][Full Text] [Related]
8. Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization.
Adar R; Monsonego-Ornan E; David P; Yayon A
J Bone Miner Res; 2002 May; 17(5):860-8. PubMed ID: 12009017
[TBL] [Abstract][Full Text] [Related]
9. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans.
Logié A; Dunois-Lardé C; Rosty C; Levrel O; Blanche M; Ribeiro A; Gasc JM; Jorcano J; Werner S; Sastre-Garau X; Thiery JP; Radvanyi F
Hum Mol Genet; 2005 May; 14(9):1153-60. PubMed ID: 15772091
[TBL] [Abstract][Full Text] [Related]
10. A novel tyrosine kinase inhibitor restores chondrocyte differentiation and promotes bone growth in a gain-of-function Fgfr3 mouse model.
Jonquoy A; Mugniery E; Benoist-Lasselin C; Kaci N; Le Corre L; Barbault F; Girard AL; Le Merrer Y; Busca P; Schibler L; Munnich A; Legeai-Mallet L
Hum Mol Genet; 2012 Feb; 21(4):841-51. PubMed ID: 22072392
[TBL] [Abstract][Full Text] [Related]
11. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia.
Naski MC; Wang Q; Xu J; Ornitz DM
Nat Genet; 1996 Jun; 13(2):233-7. PubMed ID: 8640234
[TBL] [Abstract][Full Text] [Related]
12. Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype.
Murakami S; Balmes G; McKinney S; Zhang Z; Givol D; de Crombrugghe B
Genes Dev; 2004 Feb; 18(3):290-305. PubMed ID: 14871928
[TBL] [Abstract][Full Text] [Related]
13. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation.
Martínez-Torrecuadrada J; Cifuentes G; López-Serra P; Saenz P; Martínez A; Casal JI
Clin Cancer Res; 2005 Sep; 11(17):6280-90. PubMed ID: 16144932
[TBL] [Abstract][Full Text] [Related]
14. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism.
Su WC; Kitagawa M; Xue N; Xie B; Garofalo S; Cho J; Deng C; Horton WA; Fu XY
Nature; 1997 Mar; 386(6622):288-92. PubMed ID: 9069288
[TBL] [Abstract][Full Text] [Related]
15. Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix.
Wu R; Connolly D; Ngelangel C; Bosch FX; Muñoz N; Cho KR
Oncogene; 2000 Nov; 19(48):5543-6. PubMed ID: 11114733
[TBL] [Abstract][Full Text] [Related]
16. Expression of FGFR3 with the G380R achondroplasia mutation inhibits proliferation and maturation of CFK2 chondrocytic cells.
Henderson JE; Naski MC; Aarts MM; Wang D; Cheng L; Goltzman D; Ornitz DM
J Bone Miner Res; 2000 Jan; 15(1):155-65. PubMed ID: 10646125
[TBL] [Abstract][Full Text] [Related]
17. Expression of fibroblast growth factor receptor 3 by fibroblast growth factor 2 in cultured chick embryo chondrocytes.
Suh JY; Kim YS; Park JW; Sonn JK; Kim WT
Cell Biol Int; 2005 Mar; 29(3):203-12. PubMed ID: 15878293
[TBL] [Abstract][Full Text] [Related]
18. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3.
Colvin JS; Bohne BA; Harding GW; McEwen DG; Ornitz DM
Nat Genet; 1996 Apr; 12(4):390-7. PubMed ID: 8630492
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel variant form of fibroblast growth factor receptor 3 (FGFR3 IIIb) in human colonic epithelium.
Murgue B; Tsunekawa S; Rosenberg I; deBeaumont M; Podolsky DK
Cancer Res; 1994 Oct; 54(19):5206-11. PubMed ID: 7923141
[TBL] [Abstract][Full Text] [Related]
20. Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia.
Cho JY; Guo C; Torello M; Lunstrum GP; Iwata T; Deng C; Horton WA
Proc Natl Acad Sci U S A; 2004 Jan; 101(2):609-14. PubMed ID: 14699054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
